Evidence map›Paper›PMID 28434812›Full record

ArticleJournal of dermatological science2017

ITK inhibition for the targeted treatment of CTCL.

Itzel Bustos-Villalobos, Jennifer Williams Bergstrom, Nathan E Haigh, Jesus I Luna, Anupam Mitra, Alina I Marusina, Alexander A Merleev, Elizabeth A Wang, Andrea Sukhov, Hawa Sultani and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of dermatological science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Itzel Bustos-VillalobosDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Jennifer Williams BergstromDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Nathan E HaighDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Jesus I LunaDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Anupam MitraDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Alina I MarusinaDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Alexander A MerleevDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Elizabeth A WangDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Andrea SukhovDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Hawa SultaniDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Ruiwu LiuDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Gaurav BhardwajDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Wenchang GuoDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Hsing-Jien KungDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Emanual MaverakisDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA. Electronic address: emaverakis@ucdavis.edu.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Investigation and Development of New Therapeutic Avenues for SclerodermaDP2OD008752 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MAVERAKIS, EMANUAL M. · 2011 to 2016
$2.8M
Tyrosine Kinases and Prostate CancerR01CA165263 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUNG, HSING-JIEN · 2012 to 2016
$1.7M
Androgen Signaling and Coactivator Regulation in PCAR01CA150197 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUNG, HSING-JIEN · 2010 to 2014
$1.7M
Discovery of Death Ligands Against CancersR33CA160132 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2012 to 2014
$1.0M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA150197NCI NIH HHS R01 CA165263NCI NIH HHS R33 CA160132NIH HHS DP2 OD008752
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsApoptosisBcl-2-Like Protein 11Cell Line, TumorDrug Screening Assays, AntitumorHumansLymphoma, T-Cell, CutaneousMolecular Docking SimulationProtein DomainsProtein Kinase InhibitorsProtein-Tyrosine KinasesStructure-Activity RelationshipAntineoplastic AgentsBCL2L11 protein, humanBcl-2-Like Protein 11emt protein-tyrosine kinaseProtein Kinase InhibitorsProtein-Tyrosine Kinases

Identifiers

PMID28434812
PMCPMC6459605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.